ECSP14013309A - 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos - Google Patents
2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticosInfo
- Publication number
- ECSP14013309A ECSP14013309A ECSP14013309A ECSP14013309A EC SP14013309 A ECSP14013309 A EC SP14013309A EC SP14013309 A ECSP14013309 A EC SP14013309A EC SP14013309 A ECSP14013309 A EC SP14013309A
- Authority
- EC
- Ecuador
- Prior art keywords
- tazols
- iloxi
- croman
- replaced
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a 2-(croman-6-iloxi)-tiazoles sustituidos de la fórmula I,en donde Ar, R2, R3 y R4 son como se define en las reivindicaciones. Los compuestos de fórmula son inhibidores del intercambiador de sodio y calcio (NCX), especialmente del intercambiador de sodio y calcio del subtipo 1 (NCX1), y son adecuados para el tratamiento de diversos trastornos tales como arritmias, insuficiencia cardiaca e ictus, en donde la homeostasis del calcio intracelular está alterada. La invención se refiere además a procedimientos para la preparación de los compuestos de la fórmula I, a su uso como productos farmacéuticos y a composiciones farmacéuticas que los comprenden.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306128.7A EP2567958B1 (en) | 2011-09-12 | 2011-09-12 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14013309A true ECSP14013309A (es) | 2014-05-31 |
Family
ID=46801528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP14013309 ECSP14013309A (es) | 2011-09-12 | 2014-04-11 | 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140243292A1 (es) |
| EP (2) | EP2567958B1 (es) |
| JP (1) | JP5941986B2 (es) |
| AR (1) | AR087822A1 (es) |
| BR (1) | BR112014005518A2 (es) |
| CO (1) | CO6930365A2 (es) |
| CR (1) | CR20140130A (es) |
| CY (2) | CY1115953T1 (es) |
| DK (2) | DK2567958T3 (es) |
| EA (1) | EA027998B1 (es) |
| EC (1) | ECSP14013309A (es) |
| ES (2) | ES2528143T3 (es) |
| GT (1) | GT201400044A (es) |
| HR (2) | HRP20160687T1 (es) |
| HU (1) | HUE029233T2 (es) |
| MX (1) | MX343176B (es) |
| NI (1) | NI201400017A (es) |
| PE (1) | PE20141121A1 (es) |
| PH (1) | PH12014500542B1 (es) |
| PL (2) | PL2567958T3 (es) |
| PT (2) | PT2567958E (es) |
| RS (2) | RS53748B1 (es) |
| SI (2) | SI2567958T1 (es) |
| TN (1) | TN2014000106A1 (es) |
| TW (1) | TWI549952B (es) |
| UA (1) | UA114407C2 (es) |
| UY (1) | UY34320A (es) |
| WO (1) | WO2013037724A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5941637B2 (ja) * | 2011-09-12 | 2016-06-29 | サノフイ | 置換２−（クロマン−６−イルオキシ）−チアゾール及び医薬としてのその使用 |
| TWI633095B (zh) * | 2013-03-08 | 2018-08-21 | 賽諾菲公司 | 經取代－６－基氧基－環烷類及其作為醫藥品之用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4168380A (en) | 1978-04-21 | 1979-09-18 | Hoffmann-La Roche Inc. | 7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid |
| JPH0967336A (ja) | 1995-09-04 | 1997-03-11 | Kanebo Ltd | 新規なイソチオウレア誘導体 |
| DE69810606T2 (de) | 1997-03-27 | 2003-10-09 | Taisho Pharmaceutical Co., Ltd. | 2-phenoxyanilinderivate |
| IL148385A0 (en) | 1999-09-10 | 2002-09-12 | Merck & Co Inc | Tyrosine kinase inhibitors |
| AU2001295951A1 (en) | 2000-10-18 | 2002-04-29 | Senju Pharmaceutical Co. Ltd. | Novel 4-benzyloxyphenyl derivative and use thereof |
| FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
| WO2004000813A1 (ja) | 2002-06-25 | 2003-12-31 | Yamanouchi Pharmaceutical Co., Ltd. | フェノキシピリジン誘導体又はその塩 |
| WO2004055280A1 (de) * | 2002-12-13 | 2004-07-01 | Hansgrohe Ag | Brausehalter |
| FI20030030A0 (fi) * | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| JP2006199941A (ja) * | 2004-12-20 | 2006-08-03 | Chisso Corp | クロマン環を有する化合物を含有する液晶組成物 |
| US20070197523A1 (en) * | 2005-12-22 | 2007-08-23 | Icagen, Inc. | Calcium channel antagonists |
| JP5092111B2 (ja) | 2007-02-05 | 2012-12-05 | トーアエイヨー株式会社 | ブトキシアニリン誘導体 |
| EP2103939A1 (en) | 2008-03-20 | 2009-09-23 | sanofi-aventis | Fluorescence based assay to detect sodium/calcium exchanger (NCX) "reverse mode" modulating compounds |
| EP2348859B1 (en) | 2008-10-01 | 2013-12-04 | Merck Sharp & Dohme Corp. | Prodrugs of oxazolidinone cetp inhibitors |
| JP5941637B2 (ja) * | 2011-09-12 | 2016-06-29 | サノフイ | 置換２−（クロマン−６−イルオキシ）−チアゾール及び医薬としてのその使用 |
| US8912224B2 (en) * | 2011-09-12 | 2014-12-16 | Sanofi | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
-
2011
- 2011-09-12 EP EP11306128.7A patent/EP2567958B1/en active Active
- 2011-09-12 ES ES11306128.7T patent/ES2528143T3/es active Active
- 2011-09-12 RS RS20150022A patent/RS53748B1/sr unknown
- 2011-09-12 DK DK11306128.7T patent/DK2567958T3/en active
- 2011-09-12 PL PL11306128T patent/PL2567958T3/pl unknown
- 2011-09-12 PT PT113061287T patent/PT2567958E/pt unknown
- 2011-09-12 SI SI201130350T patent/SI2567958T1/sl unknown
-
2012
- 2012-09-10 EA EA201490618A patent/EA027998B1/ru not_active IP Right Cessation
- 2012-09-10 JP JP2014529013A patent/JP5941986B2/ja active Active
- 2012-09-10 PT PT127562148T patent/PT2755970T/pt unknown
- 2012-09-10 BR BR112014005518A patent/BR112014005518A2/pt not_active Application Discontinuation
- 2012-09-10 AR ARP120103328A patent/AR087822A1/es unknown
- 2012-09-10 WO PCT/EP2012/067622 patent/WO2013037724A1/en not_active Ceased
- 2012-09-10 EP EP12756214.8A patent/EP2755970B1/en active Active
- 2012-09-10 PL PL12756214.8T patent/PL2755970T3/pl unknown
- 2012-09-10 MX MX2014002673A patent/MX343176B/es active IP Right Grant
- 2012-09-10 HR HRP20160687TT patent/HRP20160687T1/hr unknown
- 2012-09-10 PH PH1/2014/500542A patent/PH12014500542B1/en unknown
- 2012-09-10 HU HUE12756214A patent/HUE029233T2/en unknown
- 2012-09-10 PE PE2014000332A patent/PE20141121A1/es active IP Right Grant
- 2012-09-10 ES ES12756214.8T patent/ES2578184T3/es active Active
- 2012-09-10 SI SI201230609A patent/SI2755970T1/sl unknown
- 2012-09-10 DK DK12756214.8T patent/DK2755970T3/en active
- 2012-09-10 RS RS20160442A patent/RS54851B1/sr unknown
- 2012-09-10 UA UAA201403780A patent/UA114407C2/uk unknown
- 2012-09-11 TW TW101133072A patent/TWI549952B/zh not_active IP Right Cessation
- 2012-09-12 UY UY0001034320A patent/UY34320A/es not_active Application Discontinuation
-
2014
- 2014-03-03 NI NI201400017A patent/NI201400017A/es unknown
- 2014-03-07 GT GT201400044A patent/GT201400044A/es unknown
- 2014-03-11 TN TNP2014000106A patent/TN2014000106A1/en unknown
- 2014-03-11 US US14/204,220 patent/US20140243292A1/en not_active Abandoned
- 2014-03-18 CR CR20140130A patent/CR20140130A/es unknown
- 2014-04-08 CO CO14075065A patent/CO6930365A2/es unknown
- 2014-04-11 EC ECSP14013309 patent/ECSP14013309A/es unknown
-
2015
- 2015-01-09 HR HRP20150025AT patent/HRP20150025T1/hr unknown
- 2015-01-23 CY CY20151100076T patent/CY1115953T1/el unknown
-
2016
- 2016-06-28 CY CY20161100582T patent/CY1118141T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY31631A1 (es) | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| UY32848A (es) | Compuestos heterocíclicos de oxima | |
| DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
| MX2020005738A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| MX346143B (es) | Ligandos del receptor ep1. | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
| UY40282A (es) | Compuestos amido-heteroaromáticos | |
| ECSP14013309A (es) | 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos | |
| CA2901220C (en) | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals | |
| DOP2014000047A (es) | 2-(Croman-6-iloxi)-tiazoles sustituidos y su uso como farmacéuticos | |
| UY33214A (es) | Compuestos de aril-bencil-amina | |
| UY31289A1 (es) | Nuevos derivados de la quinoliniloxipiperidina y pirrolidina, su preparacion, composiciones farmaceuticas que los contiene y sus usos en el tratamieno de enfermedades | |
| CU20140021A7 (es) | Derivados de 2- amino-4- (piridin-2-il)-5,6- dihidro-4h-1,3- oxacina y su uso como inhibidores de bace -1 y/o bace-2 | |
| CL2014000599A1 (es) | Compuestos derivados de 2-(croman-6-iloxi)-tiazoles sustituidos, inhibidores del intercambiador de sodio calcio (ncx); proceso para prepararlos; composicion farmaceutica que los comprende; y su uso para el tratamiento de insufiencia cardiaca, arritmias cardiacas, ictus, demencia e hipertension, entre otras enfermedades. | |
| CU20100158A7 (es) | Pirrolo[2,3-d]pirimidinas y usos de las mismas como inhibidores de cinasa de tirosina |